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ABSTRACT 
 
The human neurotropic polyomavirus JC (JCV) induces a broad 
range of neural–origin tumors in experimental animals and has been 
repeatedly detected in several human cancer, most notably neural crest–
origin tumors including medulloblastomas and glioblastomas. The 
oncogenic activity of JCV is attributed to the viral early gene products, 
large T and small t antigens, as evident by results from in vitro cell 
culture and in vivo animal studies. The alternative splicing factor, 
SF2/ASF, has the capacity to exert a negative effect on transcription and 
splicing of JCV genes in glial cells through direct association with a 
specific DNA motif within the viral promoter region. In the present thesis 
is demonstrated that SF2/ASF suppresses large T antigen expression in 
JCV–transformed tumor cell lines, and the espression of SF2/ASF in such 
tumor cells thereby inhibits the transforming capacity of the viral tumor 
antigens. Moreover, down–regulation of SF2/ASF in viral–transformed 
tumor cell lines induces growth and proliferation of the tumor cells. 
Mapping analysis of the minimal peptide domain of SF2/ASF 
responsible for JCV promoter silencing and tumor suppressor activity 
suggests that amino acid residues 76 to 100 of SF2/ASF are functionally 
sufficient to suppress the growth of the tumor cells. These observations 
demonstrate a role for SF2/ASF in JCV–mediated cellular transformation 
and provide a new avenue of research to pathogenic mechanisms of JCV–
induced  tumors. 
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1. INTRODUCTION 
 
JCV is an ubiquitous human polyomavirus, very common in the 
general population, infecting 70 to 90 percent of humans; most people 
acquire JCV in childhood or adolescence. In individuals under 
immunosuppressive conditions, JCV may lead to the development of 
progressive multifocal leukoencephalopaty (PML). In addition to its role in 
the development of PML, JCV has also been shown to be associated with 
various tumors in laboratory animals and humans. 
JCV can transform primary human fetal glial cells in a similar manner 
to SV40 (Mandl et al., 1987; Major et al., 1985). JCV–transformed primary 
human cells express viral–early genes and exhibit a transformed phenotype 
(Gallia et al., 1998). Inoculation of JCV into owl and squirrel monkeys induces 
glioblastomas, neuroblastomas, and astrocytomas (London WT. et al., 1978). 
Transgenic animals expressing the JCV–early genome under the control of 
the JCV promoter develop tumors of neural origin including adrenal 
neuroblastoma, medulloblastoma, malignant peripheral nerve sheath 
tumors, and pituitary adenomas (Franks et al., 1996; Shollar et al., 2004; 
Krynska et al., 1999; Gordon et al., 2000). The oncogenic potential of JCV is 
strongly related to the expression of viral large and small tumor antigens. 
Ample evidence suggests that the mechanism of JCV–mediated 
transformation relies on the sequestration and suppression of the tumor 
suppressor proteins, p53 and the pRB family, by the viral large T antigen (T 
Ag). Binding of these tumor suppressor proteins with large T antigen appears 
to interfere with the cell cycle regulatory properties of these proteins. 
SF2/ASF (splicing factor 2/alternative splicing factor) is a member of 
the arginine/serine–rich splicing factor family and is one of the key 
regulators of alternative splicing of many genes (Manley et al., 1996;). Aside 
its role in the regulation of gene expression through the modulation of pre–
mRNA alternative splicing, SF2/ASF has also been shown to be an inducer of 
translation initiation by suppressing the activity of 4E–BP1, an inhibitor of 
cap–dependent translation (Michlewski et al., 2008).  
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Recently it has been demostrated that SF2/ASF strongly regulates JCV 
transcription by directly targeting a double stranded DNA motif within the 
viral promoter region (Sariyer et al., 2011). In this study, the expression of 
SF2/ASF in glial cells suppresses the transcription of the JCV–early proteins 
(large T antigen and small t antigen), as well as the viral–late proteins 
(agnoprotein, VP1, VP2, and VP3), resulting in abrogation of JCV propagation. 
Here, it is investigated the impact of SF2/ASF on JCV–induced transformation 
of glial cells and its effect on the maintenance of a transformed phenotype 
mediated by the JCV tumor antigens. The results show that expression of 
SF2/ASF in tumor cell lines, transformed by JCV, strongly suppresses the 
expression of large T antigen, causes the growth arrest, and induces 
apoptosis. In contrast, down–regulation of SF2/ASF in such tumor cell lines 
increases the growth and expansion rates of the cells under anchorage 
indipendent conditions. Collectively, these observations may suggest a 
significant role of SF2/ASF in JCV–mediated cellular transformation and 
provide a novel approach to target JCV–induced tumors.  
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1.1 JCV History and Classification 
 
Human polyomavirus JC is a DNA virus belonging to the taxonomic 
family Polyomavirinae that comprises 13 distinct viruses with a common 
ancestor that exhibit a limited range of host species to infect (Cole et al., 
2001). Human polyomaviruses are JCV, BKV and the newly discovered 
polyomaviruses WUV (Washington University poliomavirus) (Gaynor et al., 
2007), KIV (Karolinska Institute polyomavirus) (Allander et al., 2007) and 
MCV (Merkell cell carcinoma polyomavirus or MCPyV) (Feng et al., 2008), 
TSV (Trichodysplasia spinulosa-associated polyomavirus), HPyV6  e HPyV7  
(correlated with KIV e WUV) e HPyV9 (correlated to the African green 
monkey-derived lymphotropic polyomavirus). While these eight 
polyomavirus are defined humans and ubiquitous, SV40 is a monkey virus 
inadvertently introduced into the human context between 1955 and 1963, 
through the administration of polio vaccine produced in cell lines of monkey 
kidney SV40 found infected. It is also unknown how widespread the virus 
was among humans before the 1950s, though one study found that 12% of a 
sample of German medical students in 1952 had SV40 antibodies. It is 
thought that exist a human variant of the SV40.  Although horizontal 
transmission between people has been proposed, is not clear if this actually 
happens and if it does, how frequently it occurs (Martini et al., 2007). 
Although variations exist with respect to phylogenetic relatedness when 
different genes are used for analysis, JCV, BKV, KIV and WUV appear to group 
closely with SV40 (Gjoerup and Chang, 2010). 
The name polyoma is derived from the greek terms: poly, meaning 
many, and oma, meaning tumors, and refers to the capacity of these viruses 
to cause tumors (Magginis et al., 2009) in non – permissive hosts.  
Human Polyomavirus JC has been first identified in 1965 (Fig 1.1) by 
electron microscopy in a cases of PML (Silverman et al., 1965) and was first 
cultured and isolated in 1971 from PML brain tissue in a patient with Hodkin 
disease (Padgett et al., 1971; Gardner et al., 1971).  
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Figure 1.1. Electron micrography of JC virions. JC virions, uniform in bothsize and shape, display  
perfect alignment patterns called crystalloid arrays (Yukiko Shishido-Hara, Acta Neuropathol, 2010). 
 
Brain tissue was used to inoculate primary cultures derived from the 
human fetal brain, represented mostly by glial cells,  and the virus was 
isolated. The name of the patient involved was  John Cunningam, whose 
initials were attributed to the virus JC. The prototype strain of JCV, mostly 
utilized  in vitro and in vivo studies, is named Mad-1. 50-80% of adult 
individuals are seropositive for JCV (Major et al., 1992; Knowles et al., 2003). 
The mechanism of human-to-human transmission of JCV is unknown but is 
thought to be spread via a urine-oral route as JCV can be detected in 
untreated urban sewage. It is thought that the primary infection of JCV occur 
in the tonsils, then the virus can infect the epithelium of the kidney, where it 
established a life-long persistent infection (Dorries, 1998). 
 JCV primary infection in immunocompetent hosts is usually 
subclinical; the kidney is thought to be a major organ of JCV persistence 
during latency. Infections in humans by JCV are usually restricted by the 
actions of the immune system, particularly cell–mediated immunity and a 
defect in the generation of cytotoxic T–cells is associated with the emergence 
of JCV from latency to cause the disease PML (Koralnik, 2002). 
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1.2 Genome organization 
 
JCV shares approximately 70% of DNA sequence similarity with the 
other polyomaviruses, SV40 and BK virus, and displays a similar tripartite 
genome organization with early and late coding regions and a regulatory 
region (Yukiko Shishido–Hara, 2010), as is shown in Figure 1.2. 
 
 
 
JCV is a small, nonenveloped virus with an 40-45 nm icosahedral 
capsid containing 5- and 6-fold axes of symmetry; the viral capsid is 
comprised of the major capsid protein, VP1, arranged as 72 pentamers, each 
of which interacts with the C-terminus of one of the minor capsid proteins, 
VP2 or VP3 (Mengxi et al., 2009). The genome is a 3 x 103 kd supercoiled 
double-stranded circular DNA, closely associated with histones, and is 
packaged into chromatin (minichromosomes) which has structural 
similarities to cellular host chromatin (Gjoerup and Chang, 2010) 
Likewise the other polyomaviruses, JCV studies has focused mainly on 
a prototypical or reference strain of virus; for JCV it is the Mad-1 strain, 
composed by 5,128 bp. The viral genome is divided into two protein-coding 
regions that are transcribed in opposite directions starting from a common 
noncoding control region (NCCR). 
The viral genome is divided into three main regions: the early coding 
region, the late coding region, and the non-coding control region (NCCR) or 
regulatory region (RR). The early coding region encodes for small tumor 
antigen (t Ag) and large tumor antigen (T Ag) as well as T’ proteins (T’ 165, 
Figure 1.2. Organization of the JC virus genome 
(Strain Mad-1). A schematic representation 
showing the JCV genome is shown. Nucleotides 
are numbered relative to the Mad-1 reference 
strain (GenBank # NC_001699). Large-T 
antigen, small-t antigen, T'135, T'136 and T'165 
– three additional alternatively spliced forms of 
T-antigen (Trowbridge and Frisque, 1995), 
Agno – the late auxiliary protein, agnoprotein, 
ELP – putative early leader protein. 
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T’135 and T’ 136), created by alternative splicing of the viral early pre-
mRNA, and the late coding region encodes for the viral capsid proteins (or V 
antigens): VP1, VP2, and VP3, as well as the viral nonstructural protein 
agnoprotein. The NCCR separates the early and late coding and constitutes a 
bidirectional regulatory region in that it contains promoter/enhancer 
elements for the viral early and late genes and also contains the origin of viral 
DNA replication (Maginnis et al., 2009). 
The regulatory region can be divided into two groups, according to the 
differences within the sequences, “archetype” and “neurotropic type”. The 
archetype is found mainly in the urine of healthy individuals. The viruses 
isolated from demyelinating brains is designated as the “neurotropic type” 
and is also referred “PML–type”. The neurotropic type NCCR appear to have 
evolved from the archetype through deletions and duplications, and these 
modifications may increase the restricted tissue tropism or virulence, thus 
leading to changes in the pathogenicity of the virus (Daniel et al., 1996).  
 
1.3 Viral life cycle 
 
The JC virus begins its life cycle through the recognition of cellular 
receptors, moving toward the nucleus, where viral transcription and genome 
replication can take place. Recent studies demonstrate that JCV use an N-
linked glycoprotein with -2,3 – or -2,6-linked sialic acid (Dugan et al., 
2008). Viral protein 1 (VP1) mediates the binding to sialic acid. Recent 
studies to identify a proteinaceus receptor for JCV revealed that serotonin 
receptor 5–hydroxytryptophan (5–HT)2A facilitates the JCV entry into host 
cells. The serotonin receptor 5-HT2AR is a seven trans membrane–spanning 
G-protein–coupled receptor (GPCR) that belongs to the family of 5–HT 
serotonin receptors. It is though that 5-HT2A R is a key host–cell determinant, 
i.e correlated with the restricted JCV tropism, since is  abundantly expressed 
in the brain and in the kidney (Maginnis et al., 2009).  
After the binding to the host receptors, JCV enters cells by clathrin–
dependent endocytosis through an Eps-15 dependent mechanism. Next JCV  
is delivered to early endosomes and caveosomes. The virus traffics through 
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the cell to the nucleus where the virus life cycle takes place (Ashok  and 
Atwood, 2003). In the nucleus begins the transcription of viral genes 
occurs in a finely regulated manner. First, the early genes are transcribed.  
The promoter of the Mad-1 virus contains two 98–base pair repeats, which 
function in a bidirectional manner to regulate the expression of early and late 
genes. Many transcription factors have been identified including, AP1, NF – 1, 
NF-B, NFAT, Pur-alpha and YB -1; they can act as activator or silencer in JCV 
gene expression (Safak et al., 1999; Major et al., 1990). The JCV early mRNA is 
alternatively spliced into 5 transcripts: large T Ag, small t Ag, T’ (135), T’ 
(136), and T’(165) (Trowbridge PW. et al., 1995;). The splicing factor 
SF2/ASF, object of the studies shown in the present thesis, is a member of the 
splicing machinery (Sariyer and Khalili, 2011), moreover it is also involved in 
the post-transcriptional regulation of JCV early and late genes.  
The T-Ag is the main regulatory  protein from which depends all the 
viral functionality: T-Ag binds to the origin of DNA replication, unwinds the 
viral DNA through its helicase activity, and recruits the host–cell DNA 
polymerase to drive replication and this activity is implemented by the T’ 
proteins. Next, T Ag suppresses early genes transcription and initiates 
transcription of the late viral genes (the capsid viral is assembled in the 
nucleus), and Agno; agnoprotein is produced in JCV–infected cells and 
regulates viral transcription and replication by directly interacting with T Ag 
(Safak et al.,  2001).  After assembly of the virus in nuclear regions named 
ND10, the release of the viral particles can take place (Shishido – Hara Y. et 
al., 2004). 
 
 
1.4 Natural infection of JCV 
 
The polyomavirus JC has a limited host range; despite the fact that it 
can enter a variety of mammalian cell types, its replication is restricted to 
glial cells and B-cells precursors. Productive infection ends with cell lysis.  
JCV is able to establish a persistent infection in the kidney, that is thought to 
be the major site of persistence during latency but JCV rarely induces 
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diseases in immunocompetent individuals. The entire viral life cycle has been 
extensively studied in the context of PML, which JCV is the causative agent. 
The immunosuppressed individuals mostly prone to PML are those with 
human immunodeficiency virus (HIV) infection/AIDS (Hou et al., 2000), The 
occurrence of PML was very rare in the pre-HIV/AIDS era. Moreover, a strong 
cross-talk between HIV and JCV is thought to exist. 
The major sites of persistence for JCV are the cells of the kidney and 
urinary tract; JCV can be detected in approximately 10 to 50% of normal 
kydney samples (Grinnel et al., 1983).  
Numerous reports of JCV DNA in lymphocytes argue for the 
importance of these cells in persistence and dissemination via circulatory 
routes (Doerries et al., 2006; Chesters et al., 1983). It is not known whether 
the viruses enter a latent state or maintain a low level of viral gene 
expression and replication at these sites, although intermittent replication 
must occur as evidenced by periodic excretion of virus in the urine. 
Approximately 5% of immunocompetent individuals have BKV viruria while 
20 to 30% are actively shedding JCV (Chesters et al., 1983). How the host 
innate, humoral, and cellular immune responses control these persistent 
infections remains unknown. 
The infection by JCV occurs through inhalation or by ingestion of foods 
or beverages contaminated with the virus; after the primary infection, the 
virus is thought to localize in the kidneys or in the lymphoid organs such as 
the bone marrow, tonsils or spleen in a state of latency (White and Khalili, 
2005). During immunosuppression, it is believed that the JC virus is 
reactivated, since it is  recovered in urine and blood, mainly associated with 
lymphocytes B; in favor of this statement there is a recent work that shown 
intact JCV DNA sequences in bone marrow biopsies of patients obtained  
years before the development of PML (Leslie et al., 2010). 
JC virus is ubiquitous in the human population and approximately 50 – 
80 % of adults are seropositive, with asymptomatic infections by early 
childhood. The main question is to understand the mechanism by which the 
JC virus, which is almost ubiquitous in the population, in some cases can lead 
to diseases with a fatal outcome. 
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Figure 1.3. Possible mechanism of JCV infection (Nat Rev Neurol, 
2010 Nature Publishing Group). 
 
A variety of cell types have been reported to contain BKV and JCV 
sequences, and it has been suggested that infection of these cells may be 
involved in dissemination or persistence. There are rare reports of JCV 
sequence detection in various tissues and cells including the liver, lung, spleen, 
lymphonodes, and colorectal epithelium (Caldarelli et al., 1999; Laghi et al., 
1999). While JCV reactivation leads primarily to infection of the brain, it is 
unclear whether normal brain tissue harbors the virus. Published studies have 
reported both the presence (Caldarelli SR. et al., 1999; Elsner C. et al., 1992) and 
the absence (Chesters et al., 1983; Quinlivan et al., 1992) of JCV sequences in the 
brains of patients without PML. The presence of JC viral DNA has been 
repeatedly detected in postmortem brain tissues from patients who died from 
non-neurologic diseases (Del Valle et al., 2001) 
It is thought that JCV enters the host through infection of lymphoid cells 
and that these cells transfer the virus to B lymphocytes, and thereby to the sites 
of latency (Leslie et al., 2010), as the brain.  
BJAB and Namalwa B cell lines have been successfully tested in vitro for 
the replication of JCV (Atwood et al., 1992); the replication of JCV in B cells 
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correlates directly to the expression of the nuclear proteins that bind the viral 
promoter similar to those found in the brain (Major et al., 1990). Sequence 
studies show that the JC virus found in the bone marrow belongs to the PML-
type (Tan et al., 2009).  
It is thought that infected B cells enter circulation and deliver the virus to 
the bone marrow, where CD34 + hematopoietic precursors become infected and 
maintain latently the  viral genome. The nuclear factor (NF)-1X, which is 
required for JCV replication in the brain, seems to be essential also for CD34+ 
cells susceptibility to JCV entry (Monaco et al., 2001). In  bone marrow the viral 
DNA has been detected, but not intact infectious progeny virus, suggesting that 
JCV may be latent in these cells. If the control by immune defences dampens, the 
bone marrow latently infected CD34+ cells differentiate into mature B cells that 
can cross the blood-brain-barrier and carry the virus to the brain. In the brain, 
infected B cells release infectious virus that infects oligodendrocytes, which in 
turn replicate massively the virus leading to the severe demyelination, peculiar 
of PML. To note that in each compartment where JCV sequences of the PML-type 
are detected (B cells, bone marrow, and brain), virus expression is restricted by 
the binding of host cell transcription factors (Leslie et al., 2010).  
Of considerably importance the so-called “archetypal theory”, in which 
seems that archetypal virus and the neurotropic PML-type are two different JC 
viruses, that circulate in the human population; the archetypal virus can be 
detected in the urine of healthy individuals and in urban sewage. It has been 
proposed that it is the archetype that circulates in the human population and, 
after a primary infection, remains quiescent in the kidney or other organs ,with 
occasional excretion to the urine. Some time later, the neurotropic type (PML-
type) would originate from the archetypal virus, through sequence 
rearrangements. How and where the JCV virus evolves from the archetype to 
the neurotropic type remains to be established. One study reports that the 
viruses in PBLs were mostly of the neurotropic type (Dorries et al., 1994), while 
Azzi and collegues have shown the presence of both archetype and neurotropic 
types (Azzi et al., 1996). Also the bone marrow has been suggested as the site of 
transformation, as neurotropic type JC virus has been detected there as well.  
However, the neurotropic type virus has been detected in normal human 
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populations and  in different tissues from immunocompromised PML patients. 
Thus, it might be that the demyelinating disease could develop after primary 
infection, without requiring  the period of latency.  
 
1.5 Reactivation and disease 
 
The PML is a fatal demyelinating disease of the central nervous system 
(CNS) that is characterized by multiple foci of demyelination caused by the lytic 
infection by JCV of oligodendrocytes, the cells of the CNS that produce myelin 
(Gordon et al., 1998). PML is characterized by a triad of findings: 1) 
oligodendrocytes having enlarged nuclei with viral inclusion bodies, 2) bizarre, 
atypical astrocytes, and 3) loss of myelin with accompanying phagocytic 
infiltrate (Fig 1.4).  
 
 
 
Figure 1.4. Progressive multifocal 
leukoencephalopathy. (A) PML is 
characterized by multiple subcortical foci 
of demyelination highlighted using Luxol 
fast blue stain for myelin (original 
magnification: x20). (B) Higher 
magnification of several demyelinated 
lesions (H&E, original magnification: 
x100). (C) Bizarre astrocytes with extreme 
pleomorphism and multiple lobulated, 
atypical nuclei are characteristic cells in 
PML. (D) Immunohistochemistry for VP1 
in a bizarre astrocyte. (E) Enlarged 
oligodendrocytes with intranuclear 
eosinophilic inclusion bodies are 
pathognomonic for PML (H&E stain). (F) 
The inclusions are the site of 
acmagnification: x1000. (G) Characteristic 
icosahedral JC viral particles are shown by 
electronmicroscopy in the nucleus of an 
infected oligodendrocyte in a case of 
PMLtive viral replication as demonstrated 
by expression of the capsid protein VP1. 
D–F, original. (Del Valle,  White, and 
Khalili. Potential Mechanisms of the 
Human Polyomavirus JCV in 
NeuralOncogenesis. J Neuropathol Exp 
Neurol. 2008 August. 
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Usually this disease develops only in individuals with a severely 
compromised immune system, typically AIDS patients (about one in 20 of HIV–
infected persons )(Berger et al., 2003). Therefore, PML is considered an AIDS–
defining illness. 
Other circumstances that incur immunosuppression are also associated 
with PML, eg, autoimmune diseases, agammaglobulinemia, lymphoma, 
immunosoppressive drug treatment, cancer chemotherapy (White and Khalili., 
2006). PML patients often develop emiplegia, visual disturbances and 
subcortical dementia. Other neurological symptoms may also be found, such as 
dipoplia, monoplegia and akinesia (Berger et al., 1995). The involvement of 
multifocal areas of demyelination in these patients is usually detectable by 
magnetic resonance imaging (MRI). The prominent histopatological finding in 
PML is multiple foci of myelin loss, eosinophilic, enlarged oligodendroglial 
nuclei, and enlarged bizarre astrocytes with lobulated hypercromatic nuclei. 
The bizarre, atypical astrocytes which are visually indistinguishable from 
tumor cells in high-grade glial neoplasia may represent an infection by JCV of a 
cell type that is unable to support a fully lytic viral life cycle. Viral DNA and LT 
protein expression is detectable in astrocytes but at a much lower frequency 
and quantityPolyedral viral particles can be observed within the inclusion 
bodies of oligodendrocytes under the electron microscope.  
The incidence of PML complicating HIV/AIDS is higher than that of any 
other immunosoppressive disorder relative to their frequencies (Berger et al., 
2003). There exist specific molecular mechanisms whereby HIV-1 may 
promote JCV gene expression (Chowdhury et al., 1990), and partecipate in the 
pathogenesis of PML.  
The replication and dissemination of JCV in PML causes the death of 
oligodendrocytes and hence the development of focal areas of progressive 
demyelination. The exact cause of cell death in PML is not known. It has been 
suggested that JC virus–infected cells may undergo apoptosis (Richardson–
Burns et al., 2002). JCV T-antigen and agnoprotein may abrogate cell cycle 
check points (including p53 and pRB) and DNA repair processes in PML, which 
would serve to drive cells into S-phase where JCV replication occurs. However, 
this is in contrast with another report that suggest a necrotic mode of cell 
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death JCV-mediated in astrocyte cell culture (Seth et al., 2004). A recent study 
demonstrate that JCV infection is anti–apoptotic, allowing for completing of 
the viral lytic cycle (Pina–Oviedo et al., 2007). The number of reported cases of 
this previously rare disease has significantly increate since the 1980s due to 
the pandemic acquired immunodeficiency syndrome (AIDS); however, after 
introduction of HAART therapy, PML remains a major AIDS complication 
result in death (Gray et al., 2003). 
Paradoxically, some patients develop a deterioration associated with 
HAART treatment, known as immune reconstitution inflammatory syndrome 
(IRIS). IRIS can result from reconstitution of the immune system to recognize 
pathogens/antigens, and can be accompained by toxoplasmosis, 
cryptococcosis, and tubercolosis, as well as PML (Gray et al., 2005).  
The disease can also develop in persons with rheumatic diseases related 
or unrelated to immunosoppressive drug treatment; indeed, sistemic lupus 
erythematosus is one of the most common underlying diseases (Molloy et al., 
2008).  
PML has in 2005 been diagnosed in patients taking natalizumab 
(Tysabri) (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al., 2005; 
Van Assche et al., 2005) becoming the second largest group of PML risk, 
causing its temporary withdrawal from the market. Natalizumab is an alpha-4-
beta-1 integrin inhibitor approved for the treatment of relapsing-remitting 
multiple sclerosis (MS) and also used for the Crohn’s disease One of the 
proposed mechanism of action suggest that the blocking of leukocyte accross 
of blood-brain barrier, causes a loss of immune control in the CNS, resulting in 
the reactivation of latent JC virus in the brain. (Chen et al., 2009). 
PML in the setting of natalizumab therapy is related to cumulative 
exposure to natalizumab. As of August, 2011, there had been 150 cases of 
natalizumab-related PML documented in more than 88,000 patients exposed 
to natalizumab worldwide (Update on Tysabri and PML. National Multiple 
Sclerosis Society Web site. http://www.nationalmssociety.org/news/news-
detail/index.aspx?nid=2308. Published April 11, 2011. Updated July 6, 2011. 
Accessed July 7, 2011). The incidence of PML in natalizumab-treated patients 
varies according to the number of infusions received, but the incidence of PML 
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by each epoch of treatment exposure (1 to 24 infusions, 25 to 36 infusions, 37 
to 48 infusions) appears to have remained stable over time.  
Transplant recipients of solid organs, can  develop demyelination, likely 
due to immunosoppressive treatments used to prevent graft rejection (Schitrit 
et al., 2005).  
The oligodendrocytic myelin forming cells support full lytic replication of 
the virus causing the hallmark loss of myelin seen in PML. Infection of 
astrocytic cells results predominantly in changes in nuclear morphology, size, 
and ploidy. Whether the JCV infected astrocytes are transiently transformed is 
an intriguing conjecture (White and Khalili, 2006). There are scattered, but 
convincing case reports in the literature demonstrating expression of JCV T 
antigen in tumors of the CNS (Krynska et al., 1999; Pina-Oviedo et al., 2006); 
however, as a group, the glial neoplasms have not been associated in a 
consistent way with JCV infection.  
Oncogenicity of JC virus will be discussed in the next paragraph. 
 
 
1.6 JCV oncogenic features 
 
Beside its primary role in the develpment of PML, JCV has also been 
shown to be associated with several human tumors (Del Valle et al., 2001a). 
While the etiologic role for JCV in the development of cancer in humans 
remains to be established there are experimental and clinical evidence for a 
involvement of JCV in cancer.  
Furthemore, the ability of the JCV early protein to transform human 
fetal cells has led to the development of several cell lines that possess 
tumorigenic activity in vivo. 
The first evidence for the association of JCV with cancer came from 
reports of brain tumors found in patients with concomitant PML (Del Valle et 
al., 2001; Gallia et al., 1998). The first of these cases was reported by 
Richardson (Richardson EP, 1961), who first described PML in 1961: a patient  
with chronic lymphocytic leukemia and PML was found to have an 
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oligodendroglioma on post–mortem examination. Since the isolation of JCV, a 
large body of evidence has accumulated for its role in oncogenesis.  
JCV is able to infect and transform cells in culture: primary cultures, 
including primary human fetal glial cells, primary hamster brain cells (White 
et al., 2007), human vascular endothelial cells (Walker and Padgett, 1978). 
Almost all JCV–infected transformed cells express the viral early protein and 
they exhibit the phenotypic properties associated with transformation: growth 
in soft agar, serum-independence, changes in morphology, the ability to form 
foci in culture, and in some but not all cases, induces tumors in Nude mice 
(Gallia et al., 1998 a; Del Valle et al., 2001 a; White and Khalili., 2007).  
 
 
 
1.6.1. Animal studies 
 
The oncogenic potential of JCV has been established in several animal 
models. When the PML-type of JCV is inoculated via intraocular, 
intraperitoneal or intracerebral routes in newborn Syrian Golden hamsters, 
approximately 6 months after JCV injection, the animals develop multiple 
types of tumors of glial and neuronal origin: medulloblastoma, peripheral 
neuroblastoma, glioblastoma multiforme, astrocytoma, and primitive 
neuroectodermal tumors (Walker et al., 1973; Zu Rhein, 1983; Khalili et al., 
2003). More than 85% of animals develop CNS tumors, and this demonstrates 
the oncogenicity of JCV for tissues of  neural origin. Inoculation with the Tokio-
1 strain of JCV in newborn Sprague–Dawley rats results in the induction of 
primitive neuroectodermal tumors (Ohsumi et al., 1986). 
Immunohistochemical analysis of the tumor tissues, has detected Large T Ag in 
the nucleus of the tumor cells, but any signs of viral replication or myelin 
pathology. The age at the time of injection is significant with regard to the 
frequencies of tumor development: animals inoculated at birth have a much 
greater likelihood for developing cerebellar medulloblastomas than animals 
inoculated later in age, who more frequently developed glial-origin tumors in 
the cortex (Khalili et al., 2003).  
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Injection of  JCV into the brain of newborn rats induces in the 75% of 
the animals, primitive neuroectodermal tumors.  
Many authors report microscopic tumors in the internal granular layer 
of the cerebellum of hamsters which are actively replicating and migrating 
inward during early development (Zu Rhein and Varakis, 1979). The cells of 
the external granular layer originate in the neural crest and are thought to give 
rise to medulloblastoma in humans. In fact, the majority of the neoplasias 
observed in the hamster and rat models are tumors arising from cells of the 
neural crest, as medulloblastoma, primitive neuroectodermal tumors and glial-
origin tumors. Intracerebral injection of JCV in owl and squirrel monkeys  
results in develop of astrocytoma, neuroblastoma and glioblastoma. 
Immunoistochemical analysis of the tumor originated by JCV injection in 
monkeys reveal that monkey cells are non permissive for JCV replication 
(London et al., 1978; Major et al., 1992). 
Cells cultured from an astrocytoma arising in one owl monkey 
inoculated with JCV were found to produce spontaneously infectious JC viral 
particles, although some rearrangement of the viral regulatory region may 
have occurred (Major et al., 1987). In all, JCV remains the only human virus 
reported to induce solid tumors in non-human primates. 
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1.6.2 Transgenic mouse model 
Transgenic mice studies provide mostly of the interesting observation 
on the oncogenic potential of JCV. This is due to the fact that they contain the 
complete gene sequence for JCV T-antigen under the control of its own early 
promoter,  and the role of T-antigen can be studied in the absence of 
sequences encoding the capsid proteins. Independent lines of transgenic mice 
have been generated exhibits distinct phenotypes: transgenic mice can 
develop dysmyelinating diseases as observed in mice generated with the Mad-
4 strain of JCV, due to alterations in myelin sheath formation, perhaps 
determined by the feature of JCV to affect myelin gene expression (Devireddy 
et al., 1996); in addition these mice can also develop peripheral 
neuroblastomas and adrenal neuroblastomas. Transgenic mice carryng the  
Archetype, or kidney-derived isolate of JCV as the source of the transgene, 
develops cerebellar tumors resembling human medulloblastoma. Similar to 
peripheral neuroblastomas, these very cellular tumors have a high mitotic 
index, contain scant cytoplasm, and exhibit positivity for the neuronal marker 
synaptophysin (Khalili et al., 2003). 80% of transgenic mice develop 
medulloblastomas between 9 and 12 months of age. By immunohistochemical 
analyses of the tumoral cells from transgenic mice, has been shown that  have 
the majority of tumor cells contain high levels of T-antigen in the nucleus. Also, 
Krynska and colleagues demonstrates high levels of T-antigen protein in the 
tumor tissue in association with the tumor suppressor proteins, p53 and pRb 
(Krynska et al., 1999a, 1999b). Next they created from tumor tissue clonal 
populations of T-antigen-positive and T-antigen-negative cells, and they 
shown that only T-antigen-positive cell lines are able grown subcutaneously in 
Nude mice (Krynska et al., 2000). The behavior of those cells is due to  the fact 
that the T-antigen-negative cell lines have point mutation affecting an intron–
exon junction, which results in the expression of a smaller in-frame p53 mRNA 
species lacking exon 4 (Krynska et al., 2000). This region of p53 is located  
close to the T-antigen binding site, and therefore suggests that tumor cells may 
require the presence of T-antigen for inactivation of p53, while the cells that 
arbors mutant p53 variants are expressed, may no longer require T-antigen 
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expression (Khalili et al., 2003).  
 
 
  
 
 
 
 
Franks and colleagues have created transgenic mice with JCV T Ag under 
its own promoter and they developed neuroectodermal tumors with primitive 
origin or pituitary gland tumors (Franks et al., 1991). 
Summarizing these studies it is possible to affirm that T Ag in absence of 
viral replication, can affect myelin sheats formation leading to dysmyelination 
and that T Ag is able, in accord with its oncogenic potential, to induce tumors of 
neural origin.  
 
 
 
 
 
Figure 1.5. JCV-induced tumors in transgenic 
animals. (A) The brain of a JCVCY (archetype) 
transgenic mouse with a large, extra-axial mass in 
the pituitary region. (B) Consecutive sections of 
the brain of a mouse with an intra-axial PNET 
centered in the brainstem and infiltrating into the 
basal ganglia, (H&E stain, left panel). 
Immunohistochemistry for T-Ag (right panel) 
demonstrates protein expression by the tumor but 
not the adjacent brain. (C) PNETS are 
characterized by sheaths of closely packed 
neoplastic cells with slightly elongated nuclei 
(H&E, left panel). The tumor  (D) A pituitary tumor 
is composed of round neoplastic cells with 
abundant cytoplasm (H&E, left panel) and 
expresses cytoplasmic prolactin (middle panel) 
and nuclear T-Ag (right panel) by 
immunohistochemistry. (E) Malignant peripheral 
nerve sheath tumor (MPNST) is composed of 
fascicles of spindle-shaped cells with elongated 
nuclei (H&E, left panel). These tumors express S-
100 (middle panel) and nuclear T-Ag (right panel) 
by immunohistochemistry. 
Original magnification for all panels: x1000. (Luis 
Del Valle, Martyn K. White, and Kamel Khalili. 
Potential Mechanisms of the Human Polyomavirus 
JCV in NeuralOncogenesis. J Neuropathol Exp 
Neurol. 2008 August). 
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1.6.3    JCV and Associated human cancer 
 
The first indication that JCV can be involved in human cancer, come from 
an oligodendroglioma found in a patient with PML and Richardson reported 
“the disorder as a heretofore unrecognized complication of lymphatic leukemia 
or Hodgkin's disease, and the white matter lesions were generally discovered as 
incidental findings upon autopsy” (Richardson, 1961) . On the other hand, JCV 
has been associated with brain tumors in absence of PML lesions (Rencic et al., 
1996, Del Valle et al., 2000).  This association has not yet been explaned because 
mostly of the adult individuals are sieropositive for JC virus, with 
seroconversion occurring during adolescence. Also, while JCV DNA can be 
extracted from human tumor tissue, it is challenging to determine causality due 
to the ubiquitous nature of the virus (Khalili et al., 2003). Many authors found 
various type of brain tumors in immunocompetent individuals without PML 
(Boldorini et al., 1998). Del Valle and colleagues examined 85 samples of glial-
tumor origin and they found that 53 to 83% of tumors were positive for JCV 
DNA and T Ag expression (Del Valle et al., 2000). The types of human cancers 
associated with JCV are: gastrointestinal cancers: colorectal (Lyn et al., 2008; 
Laghi et al., 1999;), gastric (Murai et al., 2007), and esophageal (Del Valle et al., 
2005); brain cancers: glioblastomas (Boldorini et al., 2003; Delbue et al., 2005; 
Del Valle et al., 2000; Pina-Oviedo et al., 2006), oligoastrocytomas (Rencic et al., 
1996), oligodendrogliomas (Del Valle et al., 2002), and medullablastomas 
(Shiramizu et al., 2007), and lung cancer (Zheng et al., 2007). Groups have also 
reported that there is no association or involvement of JCV in these particolar 
cancers (Hayashi et al., 2001).  
In another study the JCV agnoprotein  has been called into the question: 11 
of 16 samples of medulloblastoma resulted positive for Agno DNA sequences 
and agnoprotein detection by immunohistochemistry results positive in 11 of 
20 samples of medulloblastoma 
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Association of JCV with human brain tumors 
 
The detection of the JCV early gene in many human brain tumors have 
suggests that JCV may be associated with human neoplasias in the absence of 
immunosuppression or PML. The use of sensitive molecular allowed to detect JC 
viral genomic sequences and expression of T-antigen in a variety of human 
tumor cell types. Rencic and colleagues (Rencic et al. 1996) reported the first 
case of JCV T-antigen detection in an oligoastrocytoma by PCR/Southern blot 
hybridization, immunohistochemistry, and Western blotting. This data was 
further confirmed by subsequent analysis of oligodendrogliomas, in which they 
have revealed viral DNA in 20–75% and T-antigen expression in up to 50% of 
tumors (Caldarelli et al., 2000; Del Valle et al., 2001). Other studies have 
revealed, by RT-PCR analysis and immunohistochemistry, many tumor samples 
of neural origin in association with JCV tumor antigens expression:  
astrocytomas, anaplastic astrocytic tumors, anaplastic oligodendroglial tumor, 
as well as glioblastomas and ependymomas. The presence of JCV T antigen not 
seems to be correlated with the aggressiveness or malignancy of the glial tumor 
(Safak et al., 2001; Khalili et al., 2003 ).  
Two separate studies of 43 medulloblastomas, nearly 77% were shown 
to contain viral DNA of JCV T-antigen, while 36% of the tumors analysed by 
immunohistochemistry showed nuclear positivity for T-antigen. (Del Valle et al., 
2002a). 
Medulloblastoma is the most common malignant brain tumor in children 
with nearly 70% appearing in children under the age of 16 and rarely occurring 
in individuals over 50 (Khalili et al., 2003; Molenaar and Trojanowski, 1994).  
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Figure 1.6. Histological and immunohistochemical evaluation of human tumors harboring JCV. Human 
tumors characterized by light microscopy include medulloblastoma (panel a), glioblastoma multiforme 
(panel d), and adenocarcinoma of the colon (panel g). Tumors were further characterized by 
immunohistochemistry for their expression of cell-type-specific markers confirming the tissue of origin 
including the neuronal marker, synaptophysin, expressed by medulloblastomas (panel b), the glial-specific 
marker, GFAP (panel e), and the epithelial marker cytokeratin for adenocarcinomas (panel h). 
Immunohistochemical staining for JCV T-antigen shows positive staining in the nuclei of tumor cells in all 
three tumor types (panels c, f, and i, respectively). (panels a, d, and G: hematoxylin and eosin staining; 
panels b, c, e, f, h, and i: hematoxylin counterstain; All panels: original magnification  400) 
(Khalili et al., Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene, 2003) 
 
 
In medulloblastoma has been detected mutant genes, as the catenin of 
the Wnt signaling pathway. Infrequently, mutations in the p53 gene are found.  
Agnoprotein, was detected in 69% of tumor samples (Safak et al., 2001); 
it appear involved dysregulation of the cell cycle properties due to the binding 
to p53 and upregulating transcription of the p21/WAF-1 (Darbinyan et al., 
2002). Since, in another study,  some of the medulloblastomas positive for 
agnoprotein  were negative for T-Ag, the agnoprotein may have a role in the 
development of some type of medulloblatomas, indipendently by T Ag (Safak et 
al., 2001).  
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Association with non–neural human tumors 
 
In addition to the CNS cells, JCV has also been detected in B limphocytes; 
a study reports that 60% of CNS limphoma samples were positive for T Ag DNA 
sequences  and 25% of the samples showed T Ag expression (Del Valle et al., 
2005), while any evidence of viral replication was detected. Hight percentage of 
normal tissues upper and lower  human gastrointestinal tract and colon tumors, 
have been shown JCV DNA sequences. “Due to the potential fecal-oral 
transmission of JCV, has been establish that JCV DNA is present in the upper and 
lower human gastrointestinal tract” (Riccardiello et al., 2000, 2001). These data 
were confirmed by PCR/Southern blot hybridization and 
immunohistochemistry performed for the presence of JCV: 83% of 29 tumor 
samples were found positive for JCV DNA sequences (Laghi et al., 1999), “a 
second study detected JCV DNA in 81% of 27 samples and nuclear T-antigen by 
immunohistochemistry in 63% of the samples” (Enam et al., 2002). In addition, 
approximately 44% of the colorectal tumors also contained evidence of JCV 
agnoprotein. Furthemore, the disregulation of -catenin signalling in colon 
tumor cells, seems to be related to T Ag activity (Enam et al., 2002).  
The association of JCV with human tumors and the experimental animal 
studies provide a strong basis to correlate the transforming ability of JCV and 
neoplasias.  
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1.6 Molecular basis of JCV T–antigen–mediated 
transformation 
 
JCV expresses three early proteins with regulatory functions: 1) the large 
T-Ag, 2) the small t-antigen (t-Ag) and 3) the agnoprotein encoded in the late 
region. Three splice variants of T-Ag have been reported (Trowbridge and 
Frisque, 1995). The regulatory proteins of JCV are multifunctional, in that the 
virus need to drive the cell cycle into the S-phase, then its proteins must be able 
to interact with many cellular factors and occasionally these interaction may be 
involved in malignant transformation.  
JCV T-Ag is a nuclear phosphoprotein of 688 amino acids. It is a very 
versatile protein, in that it is an essential factor for viral DNA replication: T Ag 
works as ATP-dependent replicative DNA helicase, as DNA binding and alpha-
polymerase  (White and Khalili, 2005); as part of T-Ag property to drive the 
cells into the S-phase, its interaction with several tumor suppressor proteins 
can allow an aberrant stimulation of cell cycle, and this can facilitate the 
oncogenic transformation (Khalili et al., 2006; White et al., 2004).  Some of 
the potential oncogenic  interactions with the host cell factors are listed in this 
section. Results from proteins interaction studies revealed that T Ag, in a similar 
manner of SV40,  has the capacity to bind and inactivate p53 and members of 
pRb family, leading to an uncontrolled proliferation. The interaction of T Ag 
with the oncosoppressor p53 may results in a failure of protection against DNA 
damage, as rather oncogenic transformations. The interaction of T-Ag with pRb 
activates E2F transcription factors that promote cell cycle progression (White et 
al., 2006).  
The  insulin receptor substrate 1 (IRS-1) is another factor which interact   
whit T Ag, allowing to development of medullosblastoma (Lassak et al., 2002),  
“the most prevalent solid brain tumor of childhood” (Khalili et al., 2003).  
JCV T-Ag also binds to β-catenin (Enam et al., 2002). This interaction  β-
catenin/Wnt pathway is another mechanism allowing the alterations of cellular   
transcription of c-myc and ciclin D1 and the promotion of the cellular 
transformation.  
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Recent data suggests that the protein neurofibromin-2 or merlin (NF2) is 
a positive regulator of p53 and T Ag can bind this protein leading 
to a disruption of the control system of the cell cycle mediated by p53 (Khalili et 
al., 2003,  White et al., 2004, Shollar et al., 2005). 
The T’ proteins, obtainend by alternative splicing of the pre mRNA of T 
Ag, are able to interact with pRb family and this may contribute to viral 
replication and cellular transformation (White et al., 2005). 
The other protein encoded by the early region of primate 
polyomaviruses is the 172 amino acid small t-Ag. The N-terminus of t-Ag is 
shared with the N-terminus of T-Ag but the C-terminus is a unique domain that 
is incorporated by alternative splicing of the early region primary transcript.  t 
Ag function by inhibiting the cellular phosphatase PP2A, and activating kinase 
signaling pathways of  cellular proliferation (White et al., 2004). 
“Agnoprotein expression exert profound effects on the cells, including 
dysregulation of cell cycle progression and cell accumulation at the G2/M 
phase” (Darbinyan et al., 2002;).  
Moreover, JCV have a mutagenic effect on cellular DNA.  Genomic 
stability and DNA repair were found to be significantly dysregulated by JCV 
infection. 
The complex series of activity of T-Ag expression may involve additional 
pathways: JCV infection and T-Ag expression can induces the expression of an 
anti-apoptotic protein, survivin, and this results in a  . (Ambrosini et al., 1997). 
significant decrease in apoptosis. The authors suggeste that  JCV activates this 
pathway in order to have enough time to replicate and complete its lytic cycle. 
(Pina-Oviedo et al., 2007).  
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Figure 1.7: Mechanisms of JCV T-antigen-mediated cellular transformation or 
demyelination (adapted from Khalili K et al., 2003) 
 
The current data indicate that, JCV has a mutagenic effect on cellular DNA 
and it is able to induce instability in the cell ploydia,  through the actions of T-Ag 
and agnoprotein.  
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SF2/ASF AS NEW REGULATORY PROTEIN IN JCV GENE 
EXPRESSION AND REPLICATION 
 
SF2/ASF (splicing factor 2/ alternative splicing factor) is a member of the 
arginine/serine–rich splicing factors family and iso ne of the key regulators of 
alternative splicing of many genes (Manley and Tacke, 1996). SF2/ASF was 
discovered and purified from HeLa cell nuclear extracts by two independent 
groups employing different assays (Ge et al., 1990; Krainer et al., 1990). 
SF2/ASF has a modular structure consisting of two copies of N – terminal 
RNA recognition motifs (RRM1, RRM2), followed by a C –terminal domain rich 
in Arg and Ser residues, known as the Arginine–Serine-rich (RS) domain.  
The RS domain interacts with the components of the core splicing 
apparatus to form splice site pairing, whereas the RRM1 and RRM2 domains 
determine the RNA–binding specificity. SF2/ASF is mainly localized to the 
nuclear speckles and shuttles between the cytoplasm and nucleus. Depending 
on splice site selection, SF2/ASF can negatively or positively regulate splicing. 
Beside the roles of SF2/ASF in the regulation of gene expression through 
the modulation of pre – mRNA alternative splicing, it ha salso been shown a san 
inducer of translation initiation by suppressing the activity of 4E – BP1, an 
inhibitor of cap – dependent translation (Michlewski et al., 2008). SF2/ASF has 
been shown to be an essential host protein since SF2 – deficient mice show 
embrionic lethality. In addition to its role in gene expression through the 
regulation of splicing and translation, SF2/ASF is also up – regulated in various 
human tumors, including lung, kidney, colon, pancreas, small intestine, and 
thyroid. Up – regulation of SF2/ASF in tumor cells indicates a possible role in 
malignant transformation. Furthemore, over – expression of SF2/ASF is 
sufficient to transform NIH–3T3 and Rat1 cells, and its transforming activity is 
related to aberrant splicing of the tumor suppressor, BIN1, and the kinases, 
MNK2, and S6K1 (Karni et al., 2007). 
Not surprisingly, SF2/ASF is utilized by many viruses including 
adenovirus, human papilloma virus, Rous sarcoma virus, influenza virus, herpes 
simplex virus and HIV-1 in order to regulate their gene expression upon 
infection of host cells. It has been shown that SF2/ASF binds the human 
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papilloma virus type 16 late RNA control element, HPV–16 NRE, and its 
expression is up–regulated by viral E2 protein during the differentiation of 
epithelial cells infected with the virus (McPhillips et al., 2004). Retroviruses use 
un–spliced viral mRNA for the expression of viral regulatory and structural 
proteins and genomic RNA for the maintenance of the infection. The balance 
between the usage of un–spliced and spliced RNA by the retroviruses is 
extremely important, since slight differences in splicing efficiency can lead to 
impaired viral replication. In Rous sarcoma virus–infected cells, SF2/ASF 
interacts with the negative regulator of splicing elements (NRS) on full length 
un–spliced viral RNA and inhibits splicing. SF2/ASF has been a positive 
regulator of M2 ion–channel protein mRNA of influenza virus, a negative–strand 
RNA virus, by binding to the 3’ exon on M1 RNA (Shih et al., 1996). There is 
accumulating evidence that the gene expression of HIV – 1 has also been 
influenced by SF2/ASF. The 9 kb full–length HIV genomic transcript undergoes 
a series of posttranscriptional modifications that generates viral mRNAs that 
produce viral structural and regulatory proteins. SF2/ASF binds to exonic 
splicing enhancers (ESEs) downstream of the Tat-, Rev-, Env-, splice sites and 
promotes exon definition (Bakkour et al., 2007; Caputi et al ., 2004; Keriel et al., 
2009). Therefore, SF2/ASF is thought to play a major role in the regulation of 
HIV-1 pre-mRNA splicing and has been proposed as a novel target for the 
inhibition of HIV replication. IDC16, an indole derivative that inhibits SF2/ASF 
activity, has been shown to be a strong inhibitor of the macrophage and T–cell – 
tropic strains of HIV – 1 replication (Bakkour et al., 2007). 
SF2/ASF was first discovered as a cell type specific regulator of simian 
polyomavirus 40 (SV40) gene expression at the post -transcriptional level (Ge et 
al., 1990). In a recent study (Sariyer and Khalili, 2011) has been investigated the 
impact of SF2/ASF on human polyomavirus, JCV, gene expression and viral DNA 
replication in primary human fetal astrocytes, PHFA. The authors co–
transfected/infected PHFA cells with the Mad–1 strains of JCV and with a 
plasmid ex pressing SF2/ASF in sense and antisense orientations. Viral DNA 
replication was analyzed at 8 days post–infection by Southern blotting. 
Overexpression of SF2/ASF suppressed the rate of viral replication and the 
expression of JCV proteins, VP1 and agnoprotein in PHFA cells. Expression of 
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SF2/ASF in PHFA cells also decreased the copy number of the virus during the 
course of JCV infection, suggested that decrease in viral gene expression by 
SF2/ASF had a profund impact on JCV propagation and the lytic cycle of the 
virus. The status of JCV transcripts during the course of viral infection was also 
investigated by RT-PCR. Consistent with the protein levels, over – espression of 
SF2/ASF in PHFA cells during the JCV infection completely inhibited viral early 
(T Ag) and late (VP1) mRNA production in a dose dependent manner. To 
investigate the possible impact of SF2/ASF on splicing of JCV transcripts, a  a 
plasmid containing the JCV early promoter sequences ex pressing the JCV early 
genes was co–transfected into PHFA cells with an SF2/ASF expression plasmid. 
RT-PCR analyses of alternatively spliced forms of the JCV early trasnscripts 
revealed that SF2/ASF not only suppressed the formation of spliced gene 
products (T – Ag and t-Ag), but also reduced the formation of primary 
transcripts, suggested that SF2/ASF had a negative impact on JCV transcription. 
Therefore, this study shown that overespression of SF2/ASF decreased the JCV–
early and late basal promoter activities in a dose dependent manner. These 
results revealed a novel role of SF2/ASF in trascriptional regulation. ChiP 
analyses from BSB8 cells overexpressing SF2/ASF assessed its ability to bind 
the JCV promoter; the DNA corresponding to the central region of the 98 bp 
tandem repeat, showed binding activity to SF2/ASF.  
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PURPOSE OF THE THESIS 
 
Transcriptional suppression of JCV expression by a cellular protein, 
SF2/ASF, which has been mainly studied for its regulatory roles in alternative 
splicing, is an unexpected and novel area of JCV research. JCV gene expression is 
a highly regulated process, which, in permissive cells, is under tight control of 
the viral promoter by inducible and ubiquitously expressed cellular 
transcription factors. The restricted tropism of JCV to the CNS is attributed to 
the tissue-specific expression of the viral-early promoter and large T antigen, 
which is the main regulatory protein of viral replication and transcription. 
Identification of SF2/ASF, which is ubiquitously expressed in body 
tissues, as a negative regulator of JCV tumor antigen expression may suggest a 
very important checkpoint for the regulation of JCV gene expression in 
permissive as well as nonpermissive cells.  
The studies of the present thesis are based on the hypotesis that the JCV 
gene expression in tumor cell lines is controlled by SF2/ASF. The purpose of the 
thesis is to understand wheter SF2/ASF is a critical cellular protein that 
limits/controls the expression of JCV genes, to establish the role of SF2/ASF on 
integrated JCV gene expression,as well as on the maintenance of the viral 
transformed phenotype and also whether it may constitute a novel target for 
the treatment of JCV-caused diseases. 
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2 MATERIAL AND METHODS 
 
2.1 Cell lines and cell culture. 
 
BsB8 cells were derived from primitive neuroectodermal tumors that 
developed in transgenic mice expressing the early genome of the JC virus 
(Krynska et al., 1999).  HJC-2 is a clonal subline of the HC-15 glioma cell line, 
which was established from a hamster brain tumor induced by intracerebral 
inoculation of neonatal hamsters with JCV (Wold et al., 1980; Raj et al. 1995; 
Walker et al., 1973). U-87 MG, a human malignant glioma cell line, was obtained 
from the American Type Culture Collection (ATCC). All cell lines and cultures 
were maintained at 37°C in a humidified atmosphere with 7% CO2. 
 
 
2.2 Plasmid constructs 
 
pCGT7-SF2 expression plasmid was kindly provided by Javier F. Caceres 
(Medical Research Council Human genetic Unit, Western general Hospital, 
Edinburgh EH4 2XU, Scotland). The epitope-tagged, full-length SF2/ASF 
expression plasmid was constructed by amplifying an SF2/ASF cDNA (Krainer 
et al., 1991) with specific primers and subcloning of the resulting PCR product 
as an XbaI-BamHI fragment into the pCGTHCFFLT7 expression vector. The 
resulting vector, pCGT7-SF2 is under the control of the cytomegalovirus 
enhancer/ promoter (Tanaka and Herr, 1990; Cáceres et al., 1994) but also 
includes an NH2-terminal epitope tag, MASMTGGQQMG. This epitope tag 
corresponds to the first 11 residues of the bacteriophage T7 gene 10 capsid 
protein and is recognized by the T7 tag monoclonal antibody (Novagen, Inc., 
Madison, WI). SF2/ASF domain mutations were created by using the following 
primers: SF2-Mut.RS (1–196)-forward 5′-ACCTTCCATCTAGATCGGGAGGTGGTG 
TGATTCGT-3′, SF2-Mut.RS (1–196)-reverse: 5′-ACCTTCCAGGATCCTTACCCATCA 
ACTTTAACCCGG-3′; SF2-RRM1 (1–100)-forward: 5′-ACCTTCCATCTAGATCGGGAG 
GTGGTGTGATTCGT-3′, SF2-RRM1 (1–100)-reverse: 5′-ACCTTCCAGGATCCTTA 
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GCCGCCGCCTCGGCCTGT -3′. SF2-Mut.RRM1 (101–248)-forward: 5′-
ACCTTCCATCTAGAGGCGGGGGTG GAGGTGGCGGA-3′. SF2/ASF-RRM1 mutants 
were cloned into pCGT7 vector at the Xba1 and BamH1 sites and were created 
using the following primer pairs: SF2/ASF-RRM1(1-75) forward: 5′-
ACCTTCCATCTAGATCGGGAGGTGGTGTGATTCGT- 3′, SF2/ASF-RRM1(1-75) 
reverse: 5′-TTCCAGGATCCTTAGTCGCGACCATACACCGCGTCTT- 3′, SF2/ ASF-
RRM1 (76-100) forward: 5′-ACCTTCCATCTAGAGGCTATGATTACGATGGGTA- 
3′, SF2/ASF-RRM1 (76-100) reverse: 5′-
ACCTTCCAGGATCCTTAGCCGCCGCCTCGGC CTGTT-3′, SF2/ASF-RRM1 (76-110) 
reverse: 5′-ACC TTCCAGGATCCTTAACCTCGG GGAGCTCCGC CA-3′. 
pcDNA3.1 large T antigen was amplified by using the following primers: 
Mad-1F (248–225), 5′-CTGGCTCGCAAAACATGTTCCCTT– 3′; Mad-1R (2575-
2601), 5′-TATAACCAGCTTTACTTAACAGTTGCA-3′. 
 
 
2.3 Western blot analysis 
 
Whole cell extracts were prepared in TNN buffer (150 mM NaC, 40 mM 
tris-HCL, pH 7.4, 1% NP-40, 1 mM DTT, 1 mM EDTA, and protease inhibitors) 
from BsB8 and HJC-2 cells transfected with pCG-T7-SF2/ ASF and were 
separated by SDS-PAGE and transferred onto a 0.2-μm nitrocellulose membrane 
(BioExpress, Kaysville, UT). Blots were blocked in 10% nonfat dry milk in 1x 
PBST and then incubated with one of the following primary antibodies: anti-
SV40 T-Ag Ab2 (1:5,000 in 2% milk/1x PBST, mouse; Calbiochem, San Diego, 
CA), anti-Grb2 (1:3,000 in 10% milk/1x PBST, mouse; BD Biosciences, Franklin 
Lakes, NJ), or anti-T7 (1:3,000 in 2% milk/1x PBST, mouse; Novagen, 
Gibbstown, NJ). Goat anti-mouse HRP secondary antibodies (1:5,000 in 2% 
milk/1x PBST) were applied, and an Amersham ECL Development kit (GE 
Healthcare, Fairfield, CT) was used as chemoluminescence. 
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2.4   Colony formation assay 
 
BsB8 and HJC-2 cells (5 * 105/100-mm dishes) were cotransfected either 
with pCGT7 empty vector or pCGT7-SF2/ASF and pcDNA 3.1 zeo (+) plasmids 
(1 g each). After 24 hours, transfected and untransfected control cells were 
collected by trypsinization and replated in 100-mm dishes (1* 105/100-mm 
dishes) in DMEM medium containing 10% FBS and G418 for selection (1 mM). 
Cells were maintained for 3 weeks, and the number of colonies was determined 
by fixing and staining the cells with 1% methylene blue. All experiments were 
performed in triplicate. 
 
 
2.5 Soft agar growth assay 
 
BsB8 and HCJ-2 cells (3 * 105/60-mm dishes) were either cotransfected with 
pCGT7-SF2/ ASF and pcDNA 3.1 zeo (+) plasmids or infected with lenti-
SF2/ASF-shRNA. After 24 hours, the cells were harvested and reseeded in 60-
mm dishes (5,000 cells/dish) containing 2 mL of a 0.3% agarose suspension in 
DMEM plus 10% fetal bovine serum and G418 (1 mM). Plates were incubated at 
37°C with 7% CO2 for 3 weeks. All experiments were done in triplicate. 
 
 
2.6 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5  
diphenyltetrazolium bromide) assay for cell proliferation 
 
 HJC-2, BsB8, and U-87 MG cells were plated in 6-well plates (2 * 105 cells/plate) 
and transfected either with pCGT7 vector alone or pCGT7- SF2/ASF expression 
plasmid. Seventy-two hours after transfection, cells were washed with 1x PBS 
and incubated with 1 mL of MTT working solution (DMEM with 0.5 mg/ mL 
MTT; Invitrogen, Carlsbad, CA) for 1 hour at 37°C. At the end of the incubation, 
the converted dye was vigorously resuspended with 1 mL acidic isopropanol 
(0.004 M HCL in isopropanol). The dye solution was then transferred into 1.5 
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mL eppendorf tubes and was centrifuged at 15,000 rpm for 5 minutes. The 
supernatant was transferred into new tubes, and absorbance of the converted 
dye was measured at a wavelength of 570 nm with background subtraction at 
650 nm. 
 
2.7 Flow cytometry analyses 
 
HJC-2 cells were seeded at a density of 250,000 cells in 60-mm dishes and 
transfected with 3 £gg of pCGT7 alone or with 3 ug of pCGT7-SF2/ASF 
expression plasmid. Untransfected cells were used as a control. Cells were 
harvested at 24, 48, and 72 hours posttransfection, then fixed in 70% ethanol, 
and stained for 45 minutes with Guava Cell Cycle Reagent (Guava Technologies, 
Hayward, CA), based on standard propidium iodide (PI) chemistry for 
quantification for DNA in whole cells. Cell acquisition and analyses were 
performed by the Guava Easy cycle Mini machine and software. All experiments 
were performed in triplicate. 
 
2.8 Lentiviral infection and RNA interference  
 
Lentivirus-based U6-promoted SF2/ASF shRNA constructs were generated by 
cloning PCR products carrying sense and antisense oligonucleotides of SF2/ASF 
into the pLL3.7 vector, which also express green fluorescent protein (GFP). To 
knock down the expression of large T antigen, shRNA construct was generated 
to target the nucleotide sequences 139 to 162 of the JCV large T antigen cDNA. 
PCR products carrying sense and antisense oligonucleotides of large T antigen 
were cloned into the pLL3.7 vector. The viruses were packaged in 293T (human 
embryonic kidney) cells according to the procedure described previously (Song 
et al. 2007;  Rubinson et al. 2003). HJC-2 cells were seeded in 6-well plates at 
50% confluency and were incubated with 1 mL of the viral supernatants. The 
infected cells were then kept in regular complete medium (DMEM, 10% FBS) for 
48 hours. Inspection by fluorescence microscopy confirmed the presence of 
more than 80% of GFP-positive cells after viral infection. 
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2.9 Reporter gene assays  
 
The JCV-early promoter reporter gene construct containing the viral regulatory 
region has been described previously (Akan I et al., 2006). U-87 MG cells were 
transfected with the reporter construct in the presence or absence of expression 
plasmids for SF2/ASF-FL and its various deletion mutants. At 48 hours 
posttransfection, cells were extracted with a series of freeze/thaw cycles, and 
the CAT activity of the samples was determined. 
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3 RESULTS 
 
3.1 JCV tumor antigen expression is suppressed by SF2/ASF in 
viral-transformed cell lines. 
 
The impact of SF2/ASF on JCV tumor antigen expression was tested in 
BsB8 cells, a cell line that originated from a medulloblastoma developed in a 
transgenic mouse expressing the JCV-early region (Krynska et al.,  1999), and in 
HJC-2 cells, a cell line obtained from a glioblastoma induced by intracranial 
injection of JCV in newborn hamsters (Wold et al., 1980; Raj et al., 1995). 
Both cell lines express the JCV-early gene products, large T and small t 
antigens, under the control of the JCVearly promoter. To investigate the possible 
role of SF2/ASF in regulating the expression of large T antigen, T7-tagged 
SF2/ASF was introduced into BsB8 and HJC-2 cells by transient transfection 
(Fig. 3.1). Western blot analyses of whole cell extracts from BsB8 and HJC-2 cells 
revealed that SF2/ ASF suppressed the protein expression levels of large T 
antigen as well as small t antigen in a dose-dependent manner. These results 
show that SF2/ASF down-regulates JCV tumor antigen expression in the viral-
transformed tumors. 
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Figure 3.1. SF2/ASF inhibits tumor antigen expression in JCV-transformed cell lines. (A) Western blot 
analysis of JCV tumor antigen expression in BsB8 cells. BsB8 cells were transfected with increasing 
concentrations of an SF2/ASF expression plasmid, which produces SF2/ASF in fusion with T7 as an 
expression tag. Expressions of large tumor antigen, small tumor antigen, and SF2/ASF were detected by 
specific antibodies in whole cell lysates at 48 hours posttransfection. GRB2 was probed as loading control. 
(B) Band intensities of large T antigen and small t antigen proteins from A were quantified by 
densitometric analyses and shown as a bar graph. (C) Western blot analysis of JCV large T antigen 
expression in HJC-2 cells overexpressing T7-tagged SF2/ASF. (D) Band intensity of large T antigen 
expression from C is shown as a bar graph. Levels of tumor antigen expression in all panels are presented 
as percentages relative to levels detected in untransfected control cells. 
 
 
 
3.2  SF2/ASF inhibits proliferation of JCV-transformed cells 
 
Previous studies have suggested that the transformed phenotype of BsB8 
cells is due to the expression of viral tumor antigens (Krynska et al., 2000). To 
determine the effect of SF2/ASF-mediated suppression of large T antigen 
expression on the transformed phenotype, a colony formation assay was 
conducted. BsB8 and HJC-2 cells were transiently cotransfected with T7-
SF2/ASF expression vector in combination with a plasmid carrying the G418 
resistance gene, and cells were grown for 2 to 3 weeks in G418 containing 
medium. As seen in Figure 3.2, control groups (transfected with pCGT7-empty 
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plasmid) of BsB8 and HJC-2 cells formed colonies as expected. However, 
expression of SF2/ASF in these cell lines greatly suppressed the growth of the 
cells when compared to the control groups (Fig. 3.2A and 3.2B, compare lane 1 
with lane 2).  
 
Figure 3.2. Growth inhibition of JCV-transformed tumor cells by SF2/ASF. Colony formation of 
HJC-2 and BsB8 cells overexpressing SF2/ASF. HJC-2 (A) and BsB8 (B) cells were seeded in 100-
mm plates and transfected with 10 μg of either empty plasmid or SF2/ASF expression plasmid 
along with a plasmid encoding resistance to G418. At 24 hours posttransfection, cultures were 
harvested, and equal numbers of cells (1 x 105 cells/dish) were plated in 100-mm plates 
containing DMEM plus fetal calf serum (10%) and 1 mM G418 for selection of the transfected 
cells. After incubation for 2 weeks, cells were washed with 1x PBS and fixed with solution 
containing 1% methylene blue for 10 minutes. All experiments were carried out in triplicate. 
Images depict representative data. 
 
Next, we tested the effect of SF2/ASF on the growth of HJC-2 cells under 
anchorage-independent conditions. HJC-2 cells were either transfected with T7-
SF2/ASF expression plasmid or infected with a lentivirus encoding shRNAs 
against SF2/ASF. After the optimal incubation time, cells were fixed and stained 
to visualize the colonies. As expected, HJC-2 cells formed numerous colonies in 
soft agar under anchorage-independent conditions (Fig. 3.3A, lane 1). Results 
from three independent experiments revealed that expression of SF2/ASF 
significantly inhibited colony formation on soft agar (Fig. 3.3A, lane 2). 
Moreover, HJC-2 cells infected with lentiviruses, expressing shRNA 
sequences against SF2/ASF, formed considerably more colonies than the 
control cells and those infected with control for lentivirus (Fig. 3.3A, compare 
lane 4 with lanes 1 and 3, respectively). Interestingly, down-regulation of 
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SF2/ASF in HJC-2 cells not only increased the number of the colonies formed 
but also led to the formation of colonies that were much larger in size (Fig. 3.3B 
and 3.3C), suggesting more aggressive growth of these cells under anchorage-
independent conditions.  
 
    A 
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Figure 3.3. SF2/ASF inhibits anchorage-independent growth of HJC-2 cells in soft agar. (A) 
Approximately 5 x 105 HJC-2 cells were transfected with pCDNA 3.1 plus pCGT7 (control) or 
pCGT7-SF2/ASF (SF2/ASF) constructs. Twenty-four hours after transfection, cells were 
trypsinized and counted, and 10,000 cells were seeded into soft agar media containing 1 mM 
G418, as described in Materials and Methods. In a separate set of soft agar experiments, HJC-2 
cells were plated (5 x 105) in 60-mm dishes and infected with either control lentivirus (lenti-
control) or with lentivirus containing shRNA sequence against SF2/ASF (lenti-SF2-shRNA). 
Forty-eight hours after infection, cells were trypsinized and counted, and 10,000 cells were 
seeded into soft agar media. Plates were incubated at 37°C for 3 weeks, and colonies were 
counted. Each experiment was performed in triplicate. (B) Down-regulationof SF2/ASF 
increased the growth rate of HJC-2 cells. HJC-2 cells were infected with lenti-SF2-shRNA as 
described in A. Phase, GFP, and merge images of colonies formed in soft agar were captured by 
fluorescence microscope. (C) Quantification of the size and number of the colonies from B. 
Numbers of colonies >10 mm2 were counted and shown as a bar graph. (D) Western blot 
analyses of SF2/ASF and large T antigen expression in HJC-2 cells infected with lenti-control and 
lenti-SF2/ASF-shRNA at 48 hours postinfections. Grb2 was probed in the same blots as loading 
control. The Student t test was performed to calculate P values in A and C. 
 
 
 
 
3.3 Extinction of JCV tumor antigens by SF2/ASF results in 
loss of viability and induction of apoptosis  
In the next series of experiments, we analyzed the effects of SF2/ASF on 
cellular viability of HJC-2, BsB8, and U-87 MG cells by MTT (3-(4,5-
dimethylthiazol-2-yl)- 2,5 diphenyltetrazolium bromide) assay. Cells were 
plated in 6-well plates and transfected either with pCG-T7 (empty vector) or 
pCG-T7-SF2/ASF expression plasmids. As shown in Figure 4, ectopic expression 
of SF2/ASF greatly suppressed the MTT activities of HJC-2 and BsB8 cells (Fig. 
3.4A and 3.4B, respectively). The MTT activity of the human glioblastoma cell 
line, U-87 MG, ectopically expressing SF2/ASF was also analyzed. Unlike the 
JCVtransformed cells, the MTT activity of U-87 MG cells was not affected by 
SF2/ASF (Fig. 3.4C), suggesting that SF2/ ASF-mediated suppression of tumor 
growth was specific to JCV-transformed cells. The selective growth inhibition by 
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SF2/ASF in JCV-transformed cells but not in the U-87 MG cells suggests that the 
tumor suppressor action of SF2/ASF in these cells is mainly related to the large 
T antigen down-regulation. To further confirm this, we performed 
complementation studies by transiently expressing large T antigen under a CMV 
promoter. Coexpression of large T antigen under CMV promoter significantly 
complemented the SF2/ASF-mediated inhibition of cellular viability in HJC-2 
and BsB8 cells (Fig. 3.4A [lane 4] and 3.4B [lane 4], respectively), suggesting 
that large T antigen expression was required to maintain cell viability. 
 
 
Figure 3.4. SF2/ASF-mediated loss of cell viability and induction of apoptosis in HJC-2 and BsB8 
cells. HJC-2 (A) and BsB8 (B) cells were transiently transfected with expression plasmids 
encoding SF2/ASF and large T antigen either individually or in combination. Seventy-two hours 
after transfection, MTT activities were detected. MTT activity of untransfected cells is presented 
as 100%, and MTT activity of the treated groups is presented proportionally. In parallel to MTT 
assays, Western blot analyses of large T antigen and SF2/ASF expression were detected by 
specific antibodies. GRB2 was probed as loading control. (C) U-87 MG cells were transfected 
with empty vector or an SF2/ASF expression plasmid. MTT activities were detected as described 
in A and B. 
 
To further demonstrate the effect of SF2/ASF on the survival of JCV-
transformed cells, SF2/ ASF was introduced into HJC-2 cells in increasing 
concentrations by transient transfection. Whole cell extracts were prepared at 
72 hours posttransfection, and expression of cleaved caspase- 3, a well-
documented indicator of apoptosis, was analyzed by Western blotting. As 
shown in Figure 3.4D, overexpression of SF2/ASF led to a shift of caspase 3 from 
its inactive (procaspase) to active (cleaved) form. This induction of apoptosis in 
HJC-2 cells overexpressing SF2/ ASF was further confirmed through flow 
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cytometry analysis (Fig. 3.4E). In order to determine the direct involvement of 
large T antigen in the maintenance of tumor survival, we have developed a 
lentiviral shRNA construct for the downregulation of large T antigen and 
investigated the impact of large T antigen down-regulation on the survival of 
JCVtransformed cells. As shown in Figure 3.4F, down-regulation of large T 
antigen also induced apoptosis in HJC-2 cells, as evidenced by the induction of 
active caspase-3. These studies suggest that expression of the viral tumor 
antigens is required for the proliferation and survival of these tumor cells and 
confirm the role of SF2/ASF as a tumor suppressor in JCV-induced tumor cells. 
 
 
 
Figure 3.4. (D) Induction of apoptosis by SF2/ASF in HJC-2 cells was analyzed by transient 
transfection studies. Western blot analyses of large tumor antigen, procaspase-3 (inactive), and 
cleaved caspase-3 (active) and SF2/ASF expression were detected by specific antibodies. GRB2 
was probed as loading control. 
(E) SF2/ASF-induced apoptosis in HJC-2 cells was analyzed by flow cytometry as described in 
Materials and Methods. Percentage of cells undergoing apoptosis is shown as a bar graph at 24, 
48, and 72 hours after transfections. Standard deviations reflect the results from two 
independent experiments. (F) Induction of apoptosis by direct down-regulation of large T 
antigen in HJC-2 cells. HJC-2 cells were either infected with lenti-control and lenti-SF2/ ASF-
shRNA or left uninfected. At 48 hours postinfection, expression of large tumor antigen, 
procaspase-3 (inactive), and cleaved caspase-3 (active) and SF2/ASF was detected by specific 
antibodies. Grb2 was probed as loading control. The Student t test was performed to calculate P 
values in A, B, C, and E. 
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3.4 The 76-to-100–amino acid region of SF2/ASF is sufficient 
to suppress growth of JCV-transformed cells. 
 
SF2/ASF has a modular structure (Fig. 3.5A), consisting of two copies of 
N-terminal RNA recognition motifs (RRM1, RRM1), followed by a C-terminal 
arginine-serine–rich domain (RS). We have previously reported that the RRM1 
domain has the capacity to interact with the JCV promoter and that this 
interaction mediates suppression of JCV gene transcription (Sariyer and Khalili, 
2011). To identify the region within SF2/ASF that is involved in the suppression 
of large T antigen expression, HJC-2 cells were transfected with plasmids 
expressing various deletion mutants of SF2/ASF, and large T antigen expression 
was analyzed by Western blotting (Fig. 3.5A and 3.5B). As shown in Figure 3.5B, 
wild-type SF2/ ASF (SF2-FL, lane 3) and the RRM1 domain (lane 6) sufficiently 
suppressed the expression of large T antigen. On the other hand, removal of the 
RRM1 domain (lane 5) had very low, if any, inhibitory effect on large T antigen 
expression. Further truncation mutations within RRM1 domain revealed that 
the amino acid region from 76 to 100 was sufficient to suppress large T antigen 
expression (Fig. 3.5B, compare lane 8 with lanes 6, 7, and 9). To assess the 
importance of the SF2/ASF-(76- 100) region in cell growth inhibitory function, 
we performed colony formation assay in which HJC-2 cells were transfected 
with plasmids expressing various mutations of SF2/ASF. In accordance with 
Western blot analyses (Fig. 3.5B), the plasmid encoding amino acid region 76 to 
100 led to a greater level of growth suppression compared to the amino acid 
region 1 to 75 (Fig. 5C). SF2/ASF also contains a “glycinerich domain” residing 
between amino acid residues 98 and 106. To test whether the glycine-rich 
domain had any impact on SF2/ ASF-mediated inhibition of tumor growth, we 
compared the activity of a plasmid encoding SF2/ASF-(76- 110) construct with 
the one encoding SF2/ASF-(76-100). As seen in Figure 3.5C, SF2/ASF-(76-110) 
also showed very similar growth inhibition to that seen with SF2/ASF-(76- 
100), suggesting that the glycine-rich domain does not alter the tumor 
suppressor activity of amino acid residues 76 to 100 (compare column 8 with 
column 7). Therefore, these results show that the 76-to- 100–amino acid region 
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of SF2/ASF is the minimal effective peptide for SF2/ASF-mediated growth 
inhibition of JCV-transformed cells. 
In the next series of experiments, we measured the effect of SF2/ASF 
deletion mutants on the transcription of the JCV-early promoter. U-87 MG cells 
were transiently transfected with expression plasmids encoding various 
deletion mutants of SF2/ASF and with a reporter plasmid encoding the CAT 
gene under the JCV-early regulatory region. In accordance with previous 
studies, the full-length SF2/ ASF construct (amino acids 1-248) and the RRM1 
domain (amino acids 1-100) suppressed transcription mediated by the JCV 
promoter (Fig. 3.5D, columns 3 and 4, respectively). To evaluate the importance 
of the regions within the RRM1 domain in the control of JCV gene transcription, 
we then examined the impact of the RRM1 deletion mutants on JCV promoter 
activity. The results indicate that amino acid region 1 to 75 of the RRM1 domain 
showed no significant effect on JCV transcription (Fig. 3.5D, column 3.5). On the 
other hand, amino acid region 76 to 100 of SF2/ASF effectively suppressed 
activity of the JCV promoter (Fig. 3.5D, column 6). Consistent with the tumor 
growth assays (Fig. 3.5C), expression of the glycine-rich domain in addition to 
amino acid region 76 to 100 of SF2/ASF did not cause any significant alteration 
in the rate of promoter suppression (Fig. 3.5D, compare column 7 with column 
6). These results suggest that the amino acid region 76 to 100 of SF2/ ASF is 
sufficient to suppress JCV transcription. 
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Figure 3.5. Characterization of the domain of SF2/ASF important for the suppression of large T 
antigen expression and cell growth inhibition. (A) Schematic representation of 248 amino acid 
full-length SF2/ASF and the deletion mutant constructs utilized. SF2/ASF deletion mutants were 
cloned into pCGT7 expression vector and tagged with T7. The “G” depicts the glycine-rich 
domain. (B) Western blot analysis of large T antigen in HJC-2 cells transfected with the SF2/ASF 
mutant constructs. Expression of SF2/ASF full-length and truncated mutants was analyzed by 
Western blot analysis with anti-T7 antibody. Grb2 was probed as a loading control. (C) The 
ability of SF2/ASF full-length and various mutants to inhibit HJC-2 cell growth was analyzed by 
colony formation as described above in Figure 2. (D) pBLCAT3 JCV-early reporter plasmid was 
transiently transfected into U-87 MG cells either alone or in combination with expression 
plasmids encoding various deletion mutants of SF2/ASF. CAT enzymatic activities were 
determined, and relative CAT activities are presented as a bar graph. The autoradiograph 
(above the graph) represents results from one of the three independent experiments presented 
in the graph. The Student t test was performed to calculate P values in C and D. 
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4. DISCUSSION 
 
It has been reported previously that SF2/ASF, splicing factor 
2/alternative splicing factor, inhibits JCV propagation in glial cells by targeting a 
specific DNA motif within the JCV bidirectional promoter region, leading to 
inhibition of viralearly and -late gene transcription (Sariyer et al., 2011). 
SF2/ASF-mediated inhibition of viral genes at the transcriptional level was 
specific to JCV and required the viral promoter. Previous studies have suggested 
that SF2/ASF is up-regulated in various human tumors, including lung, kidney, 
colon, pancreas, small intestine, and thyroid. Up-regulation of SF2/ASF in tumor 
cells indicates a possible role for this factor in malignant transformation. 
Furthermore, overexpression of SF2/ ASF is sufficient to transform NIH-
3T3 and Rat1 fibroblasts through aberrant splicing of the tumor suppressor, 
BIN1, and the kinases, MNK2 and S6K1 (Karni et al., 2007). In addition to the 
role of JCV in the development of the demyelinating disease, PML, JCV has also 
been associated with a broad range of tumors in humans and laboratory 
animals. In order to investigate the role of SF2/ASF in JCV-induced tumors, we 
utilized HJC-2 and BsB8 cells, which contained an integrated portion of the JC 
viral genome, which encodes large T and small t antigens under the control of 
the JCV-early promoter. Western blot analyses of HJC-2 and BsB8 cells have 
revealed that overexpression of SF2/ASF caused inhibition of tumor antigen 
expression in both cell lines, suggesting that SF2/ASF could also inhibit 
expression of JCV genes while integrated within the host chromosomes. 
Analyses of the growth characteristics of these cell lines by colony 
formation and soft agar assays revealed that SF2/ASF-mediated extinction of 
tumor antigen expression resulted in loss of the transformed characteristics of 
these cell lines. Moreover, SF2/ASF expression decreased cell viability and 
induced apoptosis in the JCVinduced tumor cells, but not in the human 
glioblastoma cell line, U-87 MG, suggesting that the tumor suppressor effect of 
SF2/ASF was specific to tumors transformed by JCV. In other words, SF2/ASF-
mediated suppression of tumor growth and induction of apoptosis were not 
related to any other cellular signal events that were specifically or directly 
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affected by SF2/ASF. Indeed, it was highly related to the viral tumor antigen 
expression, which was suppressed by SF2/ASF at the level of transcription, 
suggesting that large T antigen expression was required for maintaining the 
transformed phenotype of these tumors. This was further supported by the 
experiments involving direct downregulation of large T antigen by an shRNA 
construct, leading to induction of apoptosis in JCV-transformed cell lines. This 
observation is consistent with previous studies in JCV transgenic mice, which 
were created by JCV-early genes. Interestingly, immunohistochemical studies of 
various tumors induced in these transgenic animals revealed that a subset of 
tumor cells exhibited viral large T antigen expression (Krynska et al., 1999; 
Gordon et al., 2000) suggesting that expression of JCV tumor antigen is 
negatively regulated by host factors in a specific portion of these tumors. In 
addition, subcutaneous inoculation of the large T antigen positive cells, BsB8, in 
the flanks of nude mice resulted in rapid tumor development, while large T 
antigen negative cells did not proliferate significantly in nude mice, suggesting 
that large T antigen expression contributes to the growth of these tumors 
(Krynska et al., 1999;  Gordon et al., 2000; Krynska et al., 2000). 
JCV gene expression is a highly regulated process, which is under tight 
control of the viral promoter by inducible and ubiquitously expressed cellular 
transcription factors in permissive cells. The restricted tropism of JCV to the 
central nervous system (CNS) is attributed to the tissuespecific expression of 
the viral-early promoter and large T antigen, which is the main regulatory 
protein of viral replication and transcription.  
Identification of SF2/ASF, which is ubiquitously expressed in tissues 
throughout the body, as a negative regulator of JCV tumor antigen expression 
may suggest a very important checkpoint for the regulation of JCV gene 
expression in permissive as well as nonpermissive cells. SF2/ASF has a modular 
structure consisting of two copies of N-terminal RNA recognition motifs (RRM1, 
RRM2), followed by a C-terminal domain rich in Arg and Ser residues known as 
the arginine-serine–rich (RS) domain. The RS domain interacts with the 
components of the core-splicing apparatus to form splice site pairing, whereas 
the RRM1 and the RRM2 domains determine the RNA-binding specificity 
(Graveley et al., 2000; Sanford et al., 2001).  
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Previously, it  was demonstrated that the RRM1 domain of SF2/ASF is 
mainly responsible for the suppression of JCV gene transcription (Sariyer et al., 
2011). The  present Thesis reports data on the characterization of the minimal 
region within RRM1 domain that is involved in the suppression of JCV tumor 
antigen expression in viral-transformed cells. Results from biochemical and 
functional studies have revealed that amino acids 76 to 100 of SF2/ASF are 
sufficient to inhibit expression of the tumor antigen and the viral-early 
promoter activity. Further investigation of the interaction between this small 
peptide with the JCV promoter region and employment of computational 
chemistry to decipher the structure of the crystallized peptide may lead to the 
development of small molecules to suppress the expression of JCV genes. These 
observations provide further evidence that SF2/ASF is a critical cellular protein 
that limits/controls expression of JCV genes and may suggest a novel target for 
the treatment of JCV-caused diseases. 
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5. LIST OF FIGURES 
 
 
Figure 3.1. SF2/ASF inhibits tumor antigen expression in JCV-transformed cell 
lines. (A) Western blot analysis of JCV tumor antigen expression in BsB8 cells. 
BsB8 cells were transfected with increasing concentrations of an SF2/ASF 
expression plasmid, which produces SF2/ASF in fusion with T7 as an expression 
tag. Expressions of large tumor antigen, small tumor antigen, and SF2/ASF were 
detected by specific antibodies in whole cell lysates at 48 hours 
posttransfection. GRB2 was probed as loading control. (B) Band intensities of 
large T antigen and small t antigen proteins from A were quantified by 
densitometric analyses and shown as a bar graph. (C) Western blot analysis of 
JCV large T antigen expression in HJC-2 cells overexpressing T7-tagged 
SF2/ASF. (D) Band intensity of large T antigen expression from C is shown as a 
bar graph. Levels of tumor antigen expression in all panels are presented as 
percentages relative to levels detected in untransfected control cells. 
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Figure 3.2. Growth inhibition of JCV-transformed tumor cells by SF2/ASF. 
Colony formation of HJC-2 and BsB8 cells overexpressing SF2/ASF. HJC-2 (A) 
and BsB8 (B) cells were seeded in 100-mm plates and transfected with 10 μg of 
either empty plasmid or SF2/ASF expression plasmid along with a plasmid 
encoding resistance to G418. At 24 hours posttransfection, cultures were 
harvested, and equal numbers of cells (1 x 105 cells/dish) were plated in 100-
mm plates containing DMEM plus fetal calf serum (10%) and 1 mM G418 for 
selection of the transfected cells. After incubation for 2 weeks, cells were 
washed with 1x PBS and fixed with solution containing 1% methylene blue for 
10 minutes. All experiments were carried out in triplicate. Images depict 
representative data. 
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Figure 3.3. SF2/ASF inhibits anchorage-independent growth of HJC-2 cells in 
soft agar. (A) Approximately 5 x105 HJC-2 cells were transfected with pCDNA 
3.1 plus pCGT7 (control) or pCGT7-SF2/ASF (SF2/ASF) constructs. Twenty-four 
hours after transfection, cells were trypsinized and counted, and 10,000 cells 
were seeded into soft agar media containing 1 mM G418, as described in 
Materials and Methods. In a separate set of soft agar experiments, HJC-2 cells 
were plated (5 x 105) in 60-mm dishes and infected with either control 
lentivirus (lenti-control) or with lentivirus containing shRNA sequence against 
SF2/ASF (lenti-SF2-shRNA). Forty-eight hours after infection, cells were 
trypsinized and counted, and 10,000 cells were seeded into soft agar media. 
Plates were incubated at 37°C for 3 weeks, and colonies were counted. Each 
experiment was performed in triplicate. (B) Down-regulationof SF2/ASF 
increased the growth rate of HJC-2 cells. HJC-2 cells were infected with lenti-
SF2-shRNA as described in A. Phase, GFP, and merge images of colonies formed 
in soft agar were captured by fluorescence microscope. (C) Quantification of the 
size and number of the colonies from B. Numbers of colonies >10 mm2 were 
counted and shown as a bar graph. (D) Western blot analyses of SF2/ASF and 
large T antigen expression in HJC-2 cells infected with lenti-control and lenti-
SF2/ASF-shRNA at 48 hours postinfections. Grb2 was probed in the same blots 
as loading control. The Student t test was performed to calculate P values in A 
and C. 
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Figure 3.4. SF2/ASF-mediated loss of cell viability and induction of apoptosis in 
HJC-2 and BsB8 cells. HJC-2 (A) and BsB8 (B) cells were transiently transfected 
with expression plasmids encoding SF2/ASF and large T antigen either 
individually or in combination. Seventy-two hours after transfection, MTT 
activities were detected. MTT activity of untransfected cells is presented as 
100%, and MTT activity of the treated groups is presented proportionally. In 
parallel to MTT assays, Western blot analyses of large T antigen and SF2/ASF 
expression were detected by specific antibodies. GRB2 was probed as loading 
control. (C) U-87 MG cells were transfected with empty vector or an SF2/ASF 
expression plasmid. MTT activities were detected as described in A and B. 
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Figure 3.4. (D) Induction of apoptosis by SF2/ASF in HJC-2 cells was analyzed 
by transient transfection studies. Western blot analyses of large tumor antigen, 
procaspase-3 (inactive), and cleaved caspase-3 (active) and SF2/ASF expression 
were detected by specific antibodies. GRB2 was probed as loading control. 
(E) SF2/ASF-induced apoptosis in HJC-2 cells was analyzed by flow cytometry 
as described in Materials and Methods. Percentage of cells undergoing 
apoptosis is shown as a bar graph at 24, 48, and 72 hours after transfections. 
Standard deviations reflect the results from two independent experiments. (F) 
Induction of apoptosis by direct down-regulation of large T antigen in HJC-2 
cells. HJC-2 cells were either infected with lenti-control and lenti-SF2/ ASF-
shRNA or left uninfected. At 48 hours postinfection, expression of large tumor 
antigen, procaspase-3 (inactive), and cleaved caspase-3 (active) and SF2/ASF 
was detected by specific antibodies. Grb2 was probed as loading control. The 
Student t test was performed to calculate P values in A, B, C, and E. 
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Figure 3.5. Characterization of the domain of SF2/ASF important for the 
suppression of large T antigen expression and cell growth inhibition. (A) 
Schematic representation of 248 amino acid full-length SF2/ASF and the 
deletion mutant constructs utilized. SF2/ASF deletion mutants were cloned into 
pCGT7 expression vector and tagged with T7. The “G” depicts the glycine-rich 
domain. (B) Western blot analysis of large T antigen in HJC-2 cells transfected 
with the SF2/ASF mutant constructs. Expression of SF2/ASF full-length and 
truncated mutants was analyzed by Western blot analysis with anti-T7 
antibody. Grb2 was probed as a loading control. (C) The ability of SF2/ASF full-
length and various mutants to inhibit HJC-2 cell growth was analyzed by colony 
formation as described above in Figure 2. (D) pBLCAT3 JCV-early reporter 
plasmid was transiently transfected into U-87 MG cells either alone or in 
combination with expression plasmids encoding various deletion mutants of 
SF2/ASF. CAT enzymatic activities were determined, and relative CAT activities 
are presented as a bar graph. The autoradiograph (above the graph) represents 
results from one of the three independent experiments presented in the graph. 
The Student t test was performed to calculate P values in C and D. 
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